403 related articles for article (PubMed ID: 31396537)
1. Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
Liu Y; Zhang X; Chai S; Zhao X; Ji L
J Diabetes Res; 2019; 2019():1534365. PubMed ID: 31396537
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
Monami M; Dicembrini I; Nreu B; Andreozzi F; Sesti G; Mannucci E
Acta Diabetol; 2017 Dec; 54(12):1101-1114. PubMed ID: 28932989
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
[TBL] [Abstract][Full Text] [Related]
7. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
Drab SR
Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
[TBL] [Abstract][Full Text] [Related]
9. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
Wroge J; Williams NT
Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
[TBL] [Abstract][Full Text] [Related]
11. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
12. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
16. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Ji L; Zhan S
Endocrine; 2015 Apr; 48(3):794-803. PubMed ID: 25115635
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
Boyle JG; Livingstone R; Petrie JR
Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
19. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
